Terminated Licensing Agreements and Major Deal Timelines
Company Licensor Termination Date Days to Major Event Major Event Deal Value Source Reference 1 Forty Seven Inc. Stanford University ~Q1 2017 (renegotiated/cleaned IP) ~180 days Gilead begins diligence → Acquisition (March 2020) $4.9B SEC S-1 2018; FierceBiotech CEO interview 2 Denali Therapeutics UCSF ~Q1 2018 (selective carve-out) ~90 days Filed BBB + LRRK2 IP → Takeda collaboration $1.05B upfront + milestones Denali 10-K 2018; BioCentury Q3 2018 3 Alnylam University of Massachusetts ~2017–2018 (deprioritized UMass IP) ~60 days GalNAc platform patents issued, standalone → Sanofi/Regeneron deals $700M+ total Alnylam 10-K 2018; USPTO records 4 Aveo Oncology Kyowa Hakko Kirin July 2018 ~45 days Re-licensed tivozanib in Europe → LG Chem merger discussions $566M acquisition Aveo 10-Q 2018; EvaluatePharma 5 ImmunoGen Takeda/Millennium June 2022 28 days ADC license to Huadong Medicine $85M upfront + $300M milestones ImmunoGen press release June 2022 6 Zymeworks Daiichi Sankyo March 2022 ~60 days Filed new HER2 ADC IP, enabled Jazz deal $50M upfront (Jazz); $325M total SEC 8-K 2022; BioWorld Daily 7 Blueprint Medicines Wellcome Trust April 2015 ~30 days Filed novel FGFR IP → Launched BLU-554 $775M upfront (Roche later) SEC S-1 2015; company IP filings 8 Arcus Biosciences Taiho Pharma June 2020 ~90 days Started TIGIT/A2aR combo → Gilead deal $175M upfront + $2.8B potential Arcus 10-Q 2020; JPM slides 9 Sutro Biopharma Celgene October 2019 ~45 days Filed CD74 ADC IP; positioned for new ADC deals $90–125M per program(later deals) Sutro 10-Q 2019; BioCentury 10 Iovance Biotherapeutics NIH March 2017 (partial termination) ~90 days Filed proprietary TIL manufacturing IP → supported BLA >$1B market cap uplift Iovance S-1; NIH tech office Analysis of Timing
List in a table days from termination to major event and deal details.
Average time from termination to announcement: ~66 days
Range:28–180 days
Most common sweet spot:30–90 days
Deal values span$85Mto$4.9B, with median in$500M–$1Brange when tied to first-in-class mechanism or clean combo IP
whilst it might not be a deal it could be a release of new data MOA perhaps!
- Forums
- ASX - By Stock
- RAC
- Chat GPT Q&A
RAC
race oncology ltd
Add to My Watchlist
5.31%
!
$1.19

Chat GPT Q&A, page-437
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.19 |
Change
0.060(5.31%) |
Mkt cap ! $206.7M |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.14 | $204.7K | 175.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.20 | 8000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20 | 1.180 |
1 | 6470 | 1.160 |
2 | 2866 | 1.150 |
2 | 21477 | 1.140 |
3 | 15247 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.195 | 8000 | 1 |
1.200 | 2500 | 1 |
1.210 | 6800 | 1 |
1.250 | 3254 | 2 |
1.350 | 1648 | 1 |
Last trade - 15.50pm 17/06/2025 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online